
|Videos|May 19, 2021
Perioperative Decision-Making in HR+ Breast Cancer
Author(s)Debu Tripathy, MD
Considerations for therapeutic decision-making in adjuvant and neoadjuvant settings in early-stage HR-positive breast cancer.
Advertisement
Episodes in this series

Advertisement
Related to this article

Safusidenib showed durable responses in IDH1-mutant glioma, and ongoing trials will test the agent in oligodendroglioma, after vorasidenib, and as maintenance.

Ajai Chari, MD, discussed sequencing CAR T and bispecifics, fixed-duration therapy, emerging targets, and academic partnership in multiple myeloma.

At the 2026 Chemotherapy Foundation Symposium, Ajai Chari, MD, explained how disease pace and BCMA sequencing guide choosing CAR T or bispecifics.

In the phase 1/2 TRANSCEND CLL 004 trial, liso-cel plus ibrutinib produced a 45% CR/CRi rate in a heavily pretreated relapsed/refractory CLL/SLL population.

The FDA has assigned a target action date of June 28, 2027, for selinexor plus ruxolitinib as a therapeutic regimen for patients with myelofibrosis.

In the phase 2 TRAP trial, the median PFS after SBRT was 3.0 months with detectable ctDNA vs 7.8 months without it in oligoprogressive CRPC.

In the pivotal phase 3 REGAL trial, galinpepimut-S was generally well tolerated among patients with acute myeloid leukemia.
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves Neladalkib in Advanced ALK+ Non–Small Cell Lung Cancer
2
Lung Cancer Survival Rate Climbs to 31%, Although Screening Gaps Persist
3
FDA Grants Final Approval to Generic Binimetinib in BRAF-Mutant Melanoma, NSCLC
4
Galinpepimut-S Improves Overall Survival in Phase 3 AML Maintenance Trial
5











